Clinical Trial Update: A Clinical Study of Safety and P2Y12 Receptor Inhibition Effects of Ticagrelor and Clopidogrel in Vietnamese Patient [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial evaluating the safety and P2Y12 receptor inhibition effects of ticagrelor versus clopidogrel in Vietnamese patients with coronary heart…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Coronary Heart Disease

Drugs mentioned

• BRILINTA (ticagrelor)
• Plavix (clopidogrel)

Snippet

Sponsor: AstraZeneca | Conditions: Coronary Heart Disease | Phase 3 | Status: WITHDRAWN